Treatment News : Janssen and ViiV Team Up for New Single-Tablet HIV Regimen

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 13, 2014

Janssen and ViiV Team Up for New Single-Tablet HIV Regimen

Janssen R&D Ireland and ViiV Healthcare are working together to develop Edurant (rilpivirine) and Tivicay (dolutegravir) into a new two-drug, single-tablet regimen to treat HIV. Janssen’s Edurant is a non-nucleoside reverse transcriptase inhibitor, and ViiV’s Tivicay is an integrase inhibitor. Together, they could offer an option for treating HIV with just two drugs instead of the standard minimum of three. Research of the combination treatment will begin in the coming months.

The companies will also study the pair for use in children.

“HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients,” Paul Stoffels, chief scientific officer of Johnson & Johnson and worldwide chairman of Janssen, said in a release. “We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens.”

To read the press releases, click here and here.

Search: Single-tablet regimen, Tivicay, dolutegravir, Edurant, rilpivirine, Janssen, ViiV Healthcare, Paul Stoffels, Johnson & Johnson.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 2 (of 2 total)    

Christopher, Canada, 2014-06-20 17:13:02
Awesome news! I long for the day when we are down to one pill a day for this condition. Thanks to all the wonderful people in the world that give their treasure and time to help the millions affected! Truly special

Frederick Wright, Jacksonville, 2014-06-19 13:41:18
This is exciting in the HIV retro experiment players’ partnership, for Johnson and Johnson-Jansen and Glaxo Smile Cline-ViVI are teaming up, not the first time that England and the USA have come together for joint ventures for more business within this AIDS cash flow of science. Bully, to these companies and thank you for the single pill, for it is becoming quite popular. We do need each other, as HIV positive person I need your drug to stay alive, seemly, and you need the US-entitlement cash

comments 1 - 2 (of 2 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.